Milk Allergy Clinical Trial
— IgE-CMAOfficial title:
Clinical and Biological Description of an Atypical IgE-mediated Cow Milk Allergy (CMA) Form With Hands and Feet Angio-oedema From the Diagnosis to Its Spontaneous Evolution and Comparison to the Typical CMA Form Without Oedema of Extremities
NCT number | NCT04318483 |
Other study ID # | 19-HPNCL-04 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 4, 2020 |
Est. completion date | May 3, 2021 |
Verified date | May 2021 |
Source | Fondation Lenval |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cow milk allergy is one of the most frequent food allergy among children. Cow milk protein's avoidance is needed until spontaneous recovery during the two first years of life. A atypical clinical form with angio-oedema of hands and feet which is associated with high rate of lactoserum's IgE might be a hope of an earlier recovery.
Status | Completed |
Enrollment | 121 |
Est. completion date | May 3, 2021 |
Est. primary completion date | April 2, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility | Inclusion Criteria: - Patients with a concordant history of IgE-mediated CMA (skin reaction within the next hours of cow milk proteins intake, regression of symptoms with avoidance of cow milk, +/- recurrence of identical symptoms when readministration) - Patients with documented positive awareness markers (skin test and/or specific IgE > 0,1 kilo units of allergen-specific IgE per liter (kUA/l )) - Patient followed at the pediatric allergology consultation at the Pediatric Hospitals of Nice Exclusion Criteria: - patients without IgE specific performed in the first month after the reaction - patients who have had only 1 documented specific IgE test |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fondation Lenval |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | kinetics of specific IgE | kinetic is defined by dosage of specific IgE (cow milk, caseine, whey proteins) from diagnostic from control to 7 months after | at inclusion | |
Secondary | comparison of specific IgE kinetics between case and control patient | Respective evolution of the kinetics of specific IgE directed against whey proteins and casein between T0 and T1 | at inclusion | |
Secondary | Clinical characteristics of allergic reaction | description of cow milk allergy : associated clinical signs, kinetics of appearance of clinical signs, kinetics of disappearance, treatment undertaken | at inclusion | |
Secondary | Clinical characteristics of patients | description of another allergy | at inclusion | |
Secondary | Age of clinical tolerance | age of clinical tolerance is defined by age of food reintroduction at home or at hospital | at inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02317952 -
Formula for Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT00968110 -
Xolair Treatment for Milk Allergic Children
|
Early Phase 1 | |
Recruiting |
NCT03309488 -
Basophil Activation Test to Diagnose Food Allergy
|
||
Completed |
NCT00328731 -
Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).
|
Phase 1/Phase 2 | |
Recruiting |
NCT05309772 -
The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy
|
N/A | |
Terminated |
NCT02719405 -
Impact of Infant Formula on Resolution of Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT01361347 -
Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children
|
Phase 4 | |
Completed |
NCT01157117 -
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
|
Phase 2 | |
Active, not recruiting |
NCT00732654 -
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03819556 -
Swedish Study of Immunotherapy for Milk Allergy in Children
|
N/A |